However, given that approximately 20–25% of all NASH patients develop HCC in the absence of cirrhosis, it would be interesting to investigate more in-depth the role of adiponectin in non-cirrhotic NAFLD-associated HCC. Here, ADIPOQ is linked to metabolic dysfunction-associated steatohepatitis.